Early resumption of cancer treatment after percutaneous coronary intervention: Impact on cardiovascular outcomes.

Document Type


Publication Date


Publication Title

JACC (Journal of the American College of Cardiology)


Background: There are no studies on the optimal timing of cancer therapy resumption after percutaneous coronary interventions (PCI). We aimed to describe the timing of cancer treatment resumption and its impact on cardiovascular outcomes after new-generation drug eluting stent (DES) implantation. Methods: Cancer patients undergoing PCI with DES at a quaternary cancer center from December 2014 to June 2017 were included. Patients with STEMI were excluded. Baseline demographics, post-PCI cardiovascular events, malignancy type, stage, and treatment were retrospectively analyzed. Results: We included 75 patients with a mean age of 65.9±10.4 years. Solid cancers were found in 53 (70.7%) patients, while 22 (29.3%) had hematologic cancers. Advanced cancer was found in 39 (52%) patients. After PCI, 34 (45.3%) patients were treated with chemotherapy, 5 (6.7%) with radiation therapy, 2 (2.7%) with surgery, and 10 (13.3%) with immunotherapy (Figure). The median time for treatment resumption after PCI was 14 days for chemotherapy and 10 days for radiation therapy. There was no significant cardiovascular mortality in patients who resumed cancer treatment as early as 10-14 days after PCI. Conclusion: Restarting chemotherapy, immunotherapy, radiation therapy, or performing cancer-related surgery as early as 2 weeks post-PCI appears to be safe from a cardiovascular standpoint. The optimal timing of cancer treatment resumption after PCI with DES for maximal survival benefits requires further study.





First Page


Last Page